Rheumatoid arthritis (RA) is a progressive disease which causes chronic inflammation of the joints and mostly affects women.
In Europe, UCB’s biologic Cimzia® (certolizumab pegol), in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs), including MTX, has been inadequate. Cimzia® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. Cimzia®, in combination with MTX, is also indicated for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX or other DMARDs. Cimzia® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.
Cimzia® is indicated in the U.S. for the treatment of adults with moderately to severely active rheumatoid arthritis.
Our progress on RA is part of our wider, ongoing efforts to support patients living with a range of chronic inflammatory conditions, including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). We will continue to work towards developing differentiated solutions for such diseases, to help improve patients’ quality of life for years to come.